Inhibition of Oral Tumorigenesis by Antitumor B

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

May 19, 2025

Study Completion Date

June 5, 2025

Conditions

Squamous Cell Cancer of the Oral Cavity

Interventions

DRUG

Anti-tumor B

1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).

Trial Locations (1)

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors

lead

Medical College of Wisconsin

OTHER